MX2022005145A - Dispositivos de estimulación y/o selección celular y método de uso. - Google Patents

Dispositivos de estimulación y/o selección celular y método de uso.

Info

Publication number
MX2022005145A
MX2022005145A MX2022005145A MX2022005145A MX2022005145A MX 2022005145 A MX2022005145 A MX 2022005145A MX 2022005145 A MX2022005145 A MX 2022005145A MX 2022005145 A MX2022005145 A MX 2022005145A MX 2022005145 A MX2022005145 A MX 2022005145A
Authority
MX
Mexico
Prior art keywords
methods
devices
cells
cell selection
stimulation devices
Prior art date
Application number
MX2022005145A
Other languages
English (en)
Inventor
Mateusz Pawel Poltorak
Christian Radisch
Original Assignee
Juno Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Gmbh filed Critical Juno Therapeutics Gmbh
Publication of MX2022005145A publication Critical patent/MX2022005145A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/22—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the construction of the column
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/50—Conditioning of the sorbent material or stationary liquid
    • G01N30/52—Physical parameters
    • G01N30/54—Temperature
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/161—Temperature conditioning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/60—Construction of the column
    • G01N30/6052—Construction of the column body

Landscapes

  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

En la presente se proporcionan dispositivos y métodos para seleccionar y estimular una pluralidad de células en una muestra de células usando cromatografía en columna. En algunos aspectos, se proporciona un dispositivo que comprende un miembro de control de temperatura para proporcionar calor a una fase estacionaria de cromatografía y un conector configurado para proporcionar aire a la fase estacionaria durante la cromatografía en columna. En algunos aspectos, los dispositivos y métodos proporcionados en la presente reducen el tiempo necesario para generar una población de células seleccionadas y estimuladas útiles para modificación genética y, en última instancia, terapia celular, en comparación con dispositivos y métodos existentes.
MX2022005145A 2019-10-30 2020-10-29 Dispositivos de estimulación y/o selección celular y método de uso. MX2022005145A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962928303P 2019-10-30 2019-10-30
PCT/EP2020/080476 WO2021084050A1 (en) 2019-10-30 2020-10-29 Cell selection and/or stimulation devices and methods of use

Publications (1)

Publication Number Publication Date
MX2022005145A true MX2022005145A (es) 2022-06-29

Family

ID=73172649

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005145A MX2022005145A (es) 2019-10-30 2020-10-29 Dispositivos de estimulación y/o selección celular y método de uso.

Country Status (10)

Country Link
EP (1) EP4051402A1 (es)
JP (1) JP2023500318A (es)
KR (1) KR20220101641A (es)
CN (1) CN114929360A (es)
AU (1) AU2020377043A1 (es)
BR (1) BR112022008023A2 (es)
CA (1) CA3159380A1 (es)
IL (1) IL292319A (es)
MX (1) MX2022005145A (es)
WO (1) WO2021084050A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4223381A1 (en) * 2022-02-02 2023-08-09 Sartorius BIA Separations d.o.o. Method of purifying or removing a target component from full plasma
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
JP2624470B2 (ja) 1984-10-02 1997-06-25 バイオジェン インコーポレイテッド ストレプトアビジン様ポリペプチドの製造
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
IN165717B (es) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
AU650085B2 (en) 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
ES2240962T3 (es) 1993-06-04 2005-10-16 The United States Of America As Represented By The Secretary Of The Navy Metodo para estimular selectivamente la proliferacion de celulas t.
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
EP0815121A4 (en) 1995-02-09 1999-09-01 Univ Washington MODIFIED AFFINITY STREPTAVIDINE
CA2222035A1 (en) 1995-04-11 1997-03-27 Trustees Of Boston University Streptavidin mutants
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
AU6467796A (en) 1996-04-24 1997-05-15 Claude Fell Cell separation system for biological fluids like blood
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
EP0977770A4 (en) 1997-03-14 2000-04-05 Univ Boston DIFFERENTLY FLAVORED STREPTAVIDINE
JP2001519143A (ja) 1997-10-02 2001-10-23 スノル・モレキュラー・コーポレーション 可溶性の一本鎖ｔ細胞レセプタータンパク質
US5985658A (en) 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
NZ507887A (en) 1998-05-19 2002-12-20 Avidex Ltd Soluble T cell receptor
DK1082141T3 (da) 1998-05-23 2005-12-05 Univ Leiden Medical Ct CD40-bindende molekyler og CTL-peptider til behandling af tumorer
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FOR PROSTATE-SPECIFIC MEMBRANE-ANTI-SPECIFIC FUSION RECEPTORS AND THEIR USE
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
WO2000038762A1 (en) 1998-12-24 2000-07-06 Biosafe S.A. Blood separation system particularly for concentrating hematopoietic stem cells
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
WO2001056603A1 (en) 2000-02-01 2001-08-09 Tanox, Inc. Cd40-binding apc-activating molecules
EP1287357A2 (en) 2000-06-02 2003-03-05 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
CA2425862C (en) 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
ATE290020T1 (de) 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
WO2007001459A2 (en) 2004-11-15 2007-01-04 Washington University Compositions and methods for modulating lymphocyte activity
FR2841905B1 (fr) 2002-07-05 2004-09-03 Centre Nat Rech Scient Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
DK1791865T3 (da) 2004-06-29 2010-11-01 Immunocore Ltd Celler der udtrykker en modificeret T-cellerecptor
WO2006041487A2 (en) * 2004-10-07 2006-04-20 Waters Investments Limited Hplc capillary column device
AU2004325035B2 (en) 2004-11-12 2011-09-08 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
MX2007011218A (es) 2005-03-23 2007-10-17 Biosafe Sa Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa.
US20100005867A1 (en) * 2006-07-17 2010-01-14 Agilent Technologies, Inc. Temperature adjustment of a fluidic sample within a fluidic device
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
EP3357338A1 (en) 2007-03-30 2018-08-08 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
RU2549701C2 (ru) 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
US10464987B2 (en) 2009-10-06 2019-11-05 Abbvie Inc. Human single-chain T cell receptors
CA2779526C (en) 2009-11-03 2022-12-06 City Of Hope Truncated epiderimal growth factor receptor (egfrt) for transduced t cell selection
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
TR201811128T4 (tr) 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
KR102134932B1 (ko) 2011-11-11 2020-07-17 프레드 헛친슨 켄서 리서치 센터 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2817625A2 (en) 2012-02-23 2014-12-31 Stage Cell Therapeutics GmbH Chromatographic isolation of cells and other complex biological materials
CN104395462B (zh) 2012-05-03 2017-09-26 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
US11185795B2 (en) * 2012-07-06 2021-11-30 Waters Technologies Corporation Techniques for thermally insulating a chromatographic column
GB2517373B (en) * 2012-07-06 2021-02-17 Waters Technologies Corp Techniques for thermally insulating a liquid chromatographic column
RS61345B1 (sr) 2012-08-20 2021-02-26 Hutchinson Fred Cancer Res Postupak i kompozicije za ćelijsku imunoterapiju
ES2743738T3 (es) 2012-10-02 2020-02-20 Memorial Sloan Kettering Cancer Center Composiciones y métodos para inmunoterapia
WO2014076277A1 (en) 2012-11-16 2014-05-22 Iba Gmbh Streptavidin muteins and methods of using them
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
MY184699A (en) 2014-04-16 2021-04-18 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
MA51794A (fr) 2014-04-23 2020-05-06 Juno Therapeutics Inc Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive
CA2984484C (en) 2014-05-02 2024-01-23 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
TWI735418B (zh) 2014-11-05 2021-08-11 美商奇諾治療有限公司 用於轉導作用及細胞處理之方法
WO2016090312A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
CN113429482A (zh) 2014-12-05 2021-09-24 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的抗体和使用方法
EP3872094A3 (en) 2014-12-05 2021-12-08 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
AU2015357526B2 (en) 2014-12-05 2022-03-17 Eureka Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
AU2018234640B2 (en) 2017-03-14 2024-03-14 Juno Therapeutics, Inc. Methods for cryogenic storage
NZ758485A (en) 2017-04-27 2024-02-23 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
JP2022512913A (ja) 2018-11-06 2022-02-07 ジュノー セラピューティクス インコーポレイテッド 遺伝子操作されたｔ細胞を作製するための方法

Also Published As

Publication number Publication date
KR20220101641A (ko) 2022-07-19
AU2020377043A1 (en) 2022-06-02
BR112022008023A2 (pt) 2022-07-12
EP4051402A1 (en) 2022-09-07
CN114929360A (zh) 2022-08-19
CA3159380A1 (en) 2021-05-06
WO2021084050A1 (en) 2021-05-06
JP2023500318A (ja) 2023-01-05
IL292319A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2022005145A (es) Dispositivos de estimulación y/o selección celular y método de uso.
MX2021005013A (es) Métodos para la selección y estimulación de células y aparatos para los mismos.
MX2020005908A (es) Proceso para producir una composicion de celulas t modificadas.
PE20191841A1 (es) Procesos para la produccion de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia
SA518391294B1 (ar) التحرير المتعدد للجينوم
EP3737206A3 (en) Heater bundle for adaptive control
TW200517096A (en) Device and method for intradermal cell implantation
DE60139926D1 (de) Methode oder apparat zur kultivierung von zellen oder gewebe
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
BRPI0512607A (pt) dispositivo para a transferência de moléculas para células que utiliza uma força elétrica
SE9704076D0 (sv) Method for permeabilisation of cell structures and use thereof
CL2018002458A1 (es) Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227)
BR112021013971A2 (pt) Composições e métodos para estimular células natural killer
MX2019000270A (es) Haz calefactor para control adaptable y metodo para reducir la fuga de corriente.
MY191776A (en) Method for preparing electrocompetent yeast cells, and method for using said cells
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CY1122993T1 (el) Μεθοδος παραγωγης για πολυδυναμα βλαστοκυτταρα που εχουν αντιγονο-ειδικο γονιδιο υποδοχεα τ κυτταρων
MX2021011608A (es) Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
BR112021019109A2 (pt) Célula rpe manipulada, composições, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método para aplicar uma terapia com fvii
PH12019501462A1 (en) Array including sequencing primer and non-sequencing entity
MX2021014008A (es) Moléculas pequeñas para tratar el cáncer, inhibir la actividad de quimiocinas y/o inducir la muerte celular.
SG11201908782XA (en) Method for converting nucleic acid sequence of cell specifically converting nucleic acid base of targeted dna using cell endogenous dna modifying enzyme, and molecular complex used therein
EA202191174A1 (ru) Способы отбора и стимуляции клеток и устройство для этого
BR112022018478A2 (pt) Dispositivo de câmara celular implantável e usos do mesmo